Matches in Wikidata for { <http://www.wikidata.org/entity/Q90358738> ?p ?o ?g. }
Showing items 1 to 53 of
53
with 100 items per page.
- Q90358738 description "article scientifique publié en 2018" @default.
- Q90358738 description "artículu científicu espublizáu en xunu de 2018" @default.
- Q90358738 description "scientific article published on 01 June 2018" @default.
- Q90358738 description "wetenschappelijk artikel" @default.
- Q90358738 description "наукова стаття, опублікована в червні 2018" @default.
- Q90358738 name "Efficacy, safety, and pharmacokinetics of the anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, tislelizumab (BGB-A317) in a phase 2, open-label, multicenter study to investigate in patients with unresectable hepatocellular carcinoma" @default.
- Q90358738 name "Efficacy, safety, and pharmacokinetics of the anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, tislelizumab (BGB-A317) in a phase 2, open-label, multicenter study to investigate in patients with unresectable hepatocellular carcinoma" @default.
- Q90358738 type Item @default.
- Q90358738 label "Efficacy, safety, and pharmacokinetics of the anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, tislelizumab (BGB-A317) in a phase 2, open-label, multicenter study to investigate in patients with unresectable hepatocellular carcinoma" @default.
- Q90358738 label "Efficacy, safety, and pharmacokinetics of the anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, tislelizumab (BGB-A317) in a phase 2, open-label, multicenter study to investigate in patients with unresectable hepatocellular carcinoma" @default.
- Q90358738 prefLabel "Efficacy, safety, and pharmacokinetics of the anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, tislelizumab (BGB-A317) in a phase 2, open-label, multicenter study to investigate in patients with unresectable hepatocellular carcinoma" @default.
- Q90358738 prefLabel "Efficacy, safety, and pharmacokinetics of the anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, tislelizumab (BGB-A317) in a phase 2, open-label, multicenter study to investigate in patients with unresectable hepatocellular carcinoma" @default.
- Q90358738 P1433 Q90358738-9967B6A4-5036-45DA-B823-9AE3A2D03E2D @default.
- Q90358738 P1476 Q90358738-26A31B9D-8F80-418E-B78C-E34149C0C4D0 @default.
- Q90358738 P2093 Q90358738-023F9E9C-6E8B-4602-997E-F58B565AD51D @default.
- Q90358738 P2093 Q90358738-109DEEA5-096B-4412-90A8-6DC0A0524C2D @default.
- Q90358738 P2093 Q90358738-197C59EB-3BDB-43AB-AB11-A9B95533BB29 @default.
- Q90358738 P2093 Q90358738-243D0DF0-84D4-4A98-9852-1CD08009EEB8 @default.
- Q90358738 P2093 Q90358738-3418D6ED-C1E9-47AB-A6D3-3F5BCB392843 @default.
- Q90358738 P2093 Q90358738-3735F296-0CF2-4773-89F8-022F6F0EA0E6 @default.
- Q90358738 P2093 Q90358738-41F70907-73A1-46D5-867D-BA01F5E80E8D @default.
- Q90358738 P2093 Q90358738-4A609AE6-D50F-4884-8477-F2E3C1CBFE06 @default.
- Q90358738 P2093 Q90358738-5FB91847-D1E1-4E33-AFAA-E7803DD08F94 @default.
- Q90358738 P2093 Q90358738-94B35930-B7C0-456B-B56A-00CC0652E843 @default.
- Q90358738 P2093 Q90358738-96316BAD-5519-49C0-ACC3-6A21B3F0A8E2 @default.
- Q90358738 P2093 Q90358738-F9B09EFC-CEE4-40C7-870E-9DE7DFDE991E @default.
- Q90358738 P304 Q90358738-75D9AB4C-3F88-43FE-AED6-B7AC2B4ECD5A @default.
- Q90358738 P31 Q90358738-108C7E5C-ECBA-4343-9C94-19F6D8D0173F @default.
- Q90358738 P356 Q90358738-219A83DE-3FF6-4EC1-B509-F7B5E4FC8BAC @default.
- Q90358738 P478 Q90358738-341E031E-8A44-4D5E-BF76-CB21F6A2824E @default.
- Q90358738 P50 Q90358738-6EE78690-342D-4286-9C12-C61F687F34C3 @default.
- Q90358738 P577 Q90358738-CA07F775-656F-4FF0-80FB-B2620A0C722E @default.
- Q90358738 P356 MDY151.099 @default.
- Q90358738 P1433 Q326122 @default.
- Q90358738 P1476 "Efficacy, safety, and pharmacokinetics of the anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, tislelizumab (BGB-A317) in a phase 2, open-label, multicenter study to investigate in patients with unresectable hepatocellular carcinoma - Trial in progress" @default.
- Q90358738 P2093 "A Cheng" @default.
- Q90358738 P2093 "A Cubillo" @default.
- Q90358738 P2093 "C Li" @default.
- Q90358738 P2093 "E Assenat" @default.
- Q90358738 P2093 "G Abou-Alfa" @default.
- Q90358738 P2093 "J Hou" @default.
- Q90358738 P2093 "J Wu" @default.
- Q90358738 P2093 "L Rimassa" @default.
- Q90358738 P2093 "M Ducreux" @default.
- Q90358738 P2093 "P Ross" @default.
- Q90358738 P2093 "S Pluntke" @default.
- Q90358738 P2093 "Z Ren" @default.
- Q90358738 P304 "v27-v28" @default.
- Q90358738 P31 Q13442814 @default.
- Q90358738 P356 "10.1093/ANNONC/MDY151.099" @default.
- Q90358738 P478 "29 Suppl 5" @default.
- Q90358738 P50 Q73534705 @default.
- Q90358738 P577 "2018-06-01T00:00:00Z" @default.